NSE filing, NSE: MOBIKWIK. Summary written from the filing by ALFA Finder's alert engine.
One Mobikwik Systems Ltd: key numbers
- Share price
- ₹216.23
- Market cap
- ₹1,710 Cr
- Revenue (annual)
- ₹1,119 Cr
- Net profit (annual)
- ₹-62.10 Cr
- P/E (TTM)
- -136.0×Sector 22.9×
- Promoter holding
- 25.21%+0.13% QoQ
- FII holding
- 3.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from One Mobikwik Systems Ltd
All →One Mobikwik Systems Board Meeting Date
One MobiKwik will hold a board meeting on November 2, 2026 to consider its Q2 and H1 FY27 unaudited results. The trading window stays closed until November 4, 2026.
One Mobikwik Systems Other Announcement
One Mobikwik Systems Ltd submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026, as per regulatory requirements.
One Mobikwik Systems Employee Stock Options
One Mobikwik Systems Limited allotted 3,14,767 equity shares to eligible employees under the MobiKwik Employee Stock Option Plan 2014 upon exercise of vested options.
One Mobikwik Systems Promoter Buying: ₹2.12 Cr
Promoter Ms. Upasana Rupkrishan Taku acquired 1,07,000 equity shares of One MobiKwik Systems through open market purchases, totaling ₹2.12 Crore.
- Value
- ₹2.12 Cr
- Promoter stake change
- +0.13%
One Mobikwik Systems Merger & Restructuring Worth ₹147.1 Cr
Mobikwik received non-convertible debentures worth ₹147.11 Crore from its subsidiary, MDSPL, as consideration for the previously announced slump sale of its Lending Services Provider Business.
- Value
- ₹147.1 Cr
One Mobikwik Systems Annual General Meeting
One MobiKwik's 18th AGM held on 22 Sep 2026 passed all resolutions including adoption of FY26 financials and re-appointment of Director Vineet Bansal. E-voting results and scrutinizer report were submitted to exchanges.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.